FINEARTS-HF is one of four phase 3 studies that Bayer is hoping to make finerenone a go-to therapy for heart failure patients, alongside the REDEFINE-HF trial of the drug as monotherapy in ...

Intensifying oral diuretic therapy was linked to worse prognosis, but not everybody is sold on its use an endpoint.

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure in the EU, fulfilling a key 2025 pipeline objective. The pharma group ...

Bayer announced the submission of a marketing authorization application to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, seeking approval of finerenone in adult patients with chronic ...

The company is also investing in local partnerships and strengthening clinical trial processes, says Shweta Rai of Bayer Pharmaceuticals.